Fidelity Investments
EPRS

Fidelity Investments’s EPIRUS BIOPHARMACEUTICALS INC COM EPRS Stock Holding History

Fidelity Investments’s Portfolio EPRS Stock Details EPRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,374,776
Closed -$3.7M – 2780
2016
Q1 		$3.7M Sell
1,374,776
-100,024
-7% -$281K ﹤0.01% 2243
2015
Q4 		$4.56M Hold
1,474,800
– – ﹤0.01% 2223
2015
Q3 		$6.52M Hold
1,474,800
– – ﹤0.01% 2098
2015
Q2 		$8.42M Hold
1,474,800
– – ﹤0.01% 2081
2015
Q1 		$13.2M Buy
+1,474,800
New +$11.8M ﹤0.01% 1899

Other funds holding EPRS

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments's EPRS Position: Q2 2016 in Review

Fidelity Investments sold out of EPIRUS BIOPHARMACEUTICALS INC COM (EPRS) in Q2 2016, closing a stake of 1,374,776 shares — an estimated $3.7M sold.

Fidelity Investments first reported a position in EPRS in Q1 2015 and held it in 5 quarters. The position peaked at $13.2M in Q1 2015. 32 funds tracked by Wall St. Rank hold EPRS as of Q2 2016.

  • Fidelity Investments reported no remaining EPIRUS BIOPHARMACEUTICALS INC COM position as of Q2 2016 after selling out during the quarter.
  • Fidelity Investments sold 1,374,776 EPIRUS BIOPHARMACEUTICALS INC COM shares in Q2 2016, an estimated $3.7M.
  • Fidelity Investments first reported a position in EPIRUS BIOPHARMACEUTICALS INC COM in Q1 2015 and held it in 5 quarters.
  • Fidelity Investments's EPIRUS BIOPHARMACEUTICALS INC COM position peaked at $13.2M in Q1 2015.
  • 32 funds tracked by Wall St. Rank held EPIRUS BIOPHARMACEUTICALS INC COM as of Q2 2016.

Based on Fidelity Investments's 13F filing for Q2 2016, filed 11 Aug 2016.